CD274 and non-small cell lung carcinoma: Additional bsAbs, including KN046 (PD-L1/CTLA-4), AK112 (PD-1/VEGF), and SHR-1701 (PD-L1/TGF-β), are progressing through phase 3 development for various NSCLC subtypes [80,147,148].